JP2003522806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522806A5 JP2003522806A5 JP2001559507A JP2001559507A JP2003522806A5 JP 2003522806 A5 JP2003522806 A5 JP 2003522806A5 JP 2001559507 A JP2001559507 A JP 2001559507A JP 2001559507 A JP2001559507 A JP 2001559507A JP 2003522806 A5 JP2003522806 A5 JP 2003522806A5
- Authority
- JP
- Japan
- Prior art keywords
- biopolymer
- conjugate
- group
- formula
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001222 biopolymer Polymers 0.000 description 32
- 238000000034 method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- -1 organic disulfide compound Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RFSLCYMUNOEIFF-UHFFFAOYSA-N 2-(3-nitropyridin-2-yl)sulfanylethanamine Chemical compound NCCSC1=NC=CC=C1[N+]([O-])=O RFSLCYMUNOEIFF-UHFFFAOYSA-N 0.000 description 1
- QLILRKBRWXALIE-UHFFFAOYSA-N 3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1 QLILRKBRWXALIE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18255800P | 2000-02-15 | 2000-02-15 | |
| US60/182,558 | 2000-02-15 | ||
| US21150800P | 2000-06-14 | 2000-06-14 | |
| US60/211,508 | 2000-06-14 | ||
| PCT/US2001/004925 WO2001060412A2 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003522806A JP2003522806A (ja) | 2003-07-29 |
| JP2003522806A5 true JP2003522806A5 (https=) | 2008-02-21 |
Family
ID=26878197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001559507A Withdrawn JP2003522806A (ja) | 2000-02-15 | 2001-02-15 | 改良された薬物送達のための生体高分子の修飾 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1263472A2 (https=) |
| JP (1) | JP2003522806A (https=) |
| AU (1) | AU2001238346A1 (https=) |
| CA (1) | CA2400205A1 (https=) |
| IL (1) | IL151024A0 (https=) |
| WO (1) | WO2001060412A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| KR20030067755A (ko) * | 2001-01-18 | 2003-08-14 | 메르크 파텐트 게엠베하 | 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질 |
| WO2004060404A1 (ja) * | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | 薬物担体 |
| WO2005000884A1 (en) * | 2003-06-05 | 2005-01-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
| CA2529486A1 (en) * | 2003-06-18 | 2004-12-23 | Nst Neurosurvival Technologies Ltd. | Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| CA2542041C (en) * | 2003-10-10 | 2014-12-09 | Cellular Bioengineering, Inc. | Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants |
| US7625736B2 (en) | 2004-06-04 | 2009-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for preparing immunogenic conjugates |
| TW200612991A (en) | 2004-09-07 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Process for producing water-soluble hyaluronic acid modification |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| WO2007008904A2 (en) | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
| SI2457920T1 (en) | 2007-01-18 | 2018-02-28 | Genzyme Corporation | Oligosaccharides containing the amino acid group and their conjugates |
| CA3040973A1 (en) | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| WO2012118189A1 (ja) | 2011-03-03 | 2012-09-07 | 中外製薬株式会社 | アミノ－カルボン酸により修飾されたヒアルロン酸誘導体 |
| WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
| JP6275044B2 (ja) | 2012-09-05 | 2018-02-07 | 中外製薬株式会社 | アミノ酸およびステリル基が導入されたヒアルロン酸誘導体 |
| KR102049568B1 (ko) * | 2013-04-01 | 2019-11-27 | 삼성전자주식회사 | 히알루론산을 포함하는 핵산전달용 조성물 |
| GB201602359D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN108440684A (zh) * | 2018-03-22 | 2018-08-24 | 华侨大学 | 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2079109A1 (en) * | 1990-03-29 | 1991-09-30 | John A. Latham | Oligonucleotide-transport agent disulfide conjugates |
| US5169934A (en) * | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
| US6335434B1 (en) * | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| EP0611306B1 (en) * | 1991-11-08 | 1998-07-08 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| US5902795A (en) | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
| US5329029A (en) | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
| BR9405798A (pt) * | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US5354853A (en) | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
| IL132941A0 (en) * | 1997-05-21 | 2001-03-19 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| US5932552A (en) | 1997-11-26 | 1999-08-03 | Keraplast Technologies Ltd. | Keratin-based hydrogel for biomedical applications and method of production |
-
2001
- 2001-02-15 WO PCT/US2001/004925 patent/WO2001060412A2/en not_active Ceased
- 2001-02-15 JP JP2001559507A patent/JP2003522806A/ja not_active Withdrawn
- 2001-02-15 IL IL15102401A patent/IL151024A0/xx unknown
- 2001-02-15 AU AU2001238346A patent/AU2001238346A1/en not_active Abandoned
- 2001-02-15 CA CA002400205A patent/CA2400205A1/en not_active Abandoned
- 2001-02-15 EP EP01910775A patent/EP1263472A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003522806A5 (https=) | ||
| US7417021B2 (en) | Biologically active conjugate of a biopolymer and therapeutic agent | |
| US20210283264A1 (en) | Polymeric Prodrugs with a Self-Immolative Linker | |
| JP5111416B2 (ja) | アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー | |
| JP4327135B2 (ja) | 酸化窒素放出生体高分子含有医薬組成物 | |
| Enescu et al. | Functionalized chitosan and its use in pharmaceutical, biomedical, and biotechnological research | |
| CA2134745A1 (en) | Glycosaminoglycan-synthetic polymer conjugates | |
| CN113599507B (zh) | 葡萄糖触发的活性氧响应注射型复合水凝胶的制备方法 | |
| Wang et al. | Injectable, adhesive albumin nanoparticle-incorporated hydrogel for sustained localized drug delivery and efficient tumor treatment | |
| ATE445417T1 (de) | Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung | |
| JP2003522806A (ja) | 改良された薬物送達のための生体高分子の修飾 | |
| WO2017101883A1 (zh) | 一种可在生理条件下降解的水凝胶 | |
| NO20052505L (no) | Ny bruk av dextran-sulfat | |
| CN114652743B (zh) | 一种基于海藻酸钠的一氧化氮供体及其合成方法和应用 | |
| CN108517003A (zh) | 成胶因子、水凝胶以及药物组合物 | |
| US9707303B2 (en) | Reduction stimulus-responsive gene delivery system and preparation and application thereof | |
| Roldo et al. | Chitosan-derivative based hydrogels as drug delivery platforms: applications in drug delivery and tissue engineering | |
| Ottenbrite et al. | Polymer systems for biomedical applications: An overview | |
| CN1424341A (zh) | 双链聚乙二醇及与蛋白质的结合物 | |
| CN108503687A (zh) | 成胶因子的制备方法和水凝胶的制备方法以及应用 | |
| JPWO1993014216A1 (ja) | 皮膚糸状菌によるキチン及びキトサンの生産方法 |